Asset Details
Do you wish to reserve the book?
PARP inhibitors for cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PARP inhibitors for cancer therapy
Do you wish to request the book?
PARP inhibitors for cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PARP inhibitors for cancer therapy
2005
Overview
Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by the base-excision pathway or cell death. A family of 18 PARPs has been identified, but only the most abundant, PARP-1 and PARP-2, which are both nuclear enzymes, are activated by DNA damage. PARP inhibitors of ever-increasing potency have been developed in the 40 years since the discovery of PARP-1, both as tools for the investigation of PARP-1 function and as potential modulators of DNA-repair-mediated resistance to cytotoxic therapy. Owing to the high level of homology between the catalytic domains of PARP-1 and PARP-2, the inhibitors probably affect both enzymes. Convincing biochemical evidence, which has been corroborated by genetic manipulation of PARP-1 activity, shows that PARP inhibition is associated with increased sensitivity to DNA-alkylating agents, topoisomerase I poisons and ionising radiation. Novel PARP inhibitors of sufficient potency and suitable pharmacokinetic properties to allow evaluation in animal models have been shown to enhance the antitumour activity of temozolomide (a DNA-methylating agent), topoisomerase poisons and ionising radiation; indeed, the combination with temozolomide resulted in complete tumour regression in two independent studies. The combination of a PARP inhibitor and temozolomide is currently undergoing clinical evaluation for the first time.
Publisher
Cambridge University Press
Subject
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Dacarbazine - administration & dosage
/ Dacarbazine - analogs & derivatives
/ DNA, Neoplasm - drug effects
/ Drug Screening Assays, Antitumor
/ Humans
/ Mice
/ Neoplasm Proteins - antagonists & inhibitors
/ Neoplasm Proteins - physiology
/ Poly (ADP-Ribose) Polymerase-1
/ Poly(ADP-ribose) Polymerase Inhibitors
/ Poly(ADP-ribose) Polymerases - chemistry
/ Poly(ADP-ribose) Polymerases - deficiency
/ Poly(ADP-ribose) Polymerases - genetics
